297 related articles for article (PubMed ID: 26675567)
1. Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives.
Matsuzaki S; Yoshino K; Ueda Y; Matsuzaki S; Kakuda M; Okazawa A; Egawa-Takata T; Kobayashi E; Kimura T
Cancer Cell Int; 2015; 15():117. PubMed ID: 26675567
[TBL] [Abstract][Full Text] [Related]
2. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary.
Kim A; Serada S; Enomoto T; Naka T
Expert Opin Ther Targets; 2010 Sep; 14(9):963-71. PubMed ID: 20673185
[TBL] [Abstract][Full Text] [Related]
3. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
4. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
5. Updates of Pathogenesis, Diagnostic and Therapeutic Perspectives for Ovarian Clear Cell Carcinoma.
Zhu C; Xu Z; Zhang T; Qian L; Xiao W; Wei H; Jin T; Zhou Y
J Cancer; 2021; 12(8):2295-2316. PubMed ID: 33758607
[TBL] [Abstract][Full Text] [Related]
6. Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic.
Gadducci A; Cosio S; Genazzani AR
Expert Rev Endocrinol Metab; 2007 Mar; 2(2):225-238. PubMed ID: 30754175
[TBL] [Abstract][Full Text] [Related]
7. Annexin A4 is a promising therapeutic target for the treatment of platinum-resistant cancers.
Matsuzaki S; Serada S; Morimoto A; Ueda Y; Yoshino K; Kimura T; Naka T
Expert Opin Ther Targets; 2014 Apr; 18(4):403-14. PubMed ID: 24479491
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of annexin A4 is associated with chemoresistance in papillary serous adenocarcinoma of the ovary.
Choi CH; Sung CO; Kim HJ; Lee YY; Song SY; Song T; Kim J; Kim TJ; Lee JW; Bae DS; Kim BG
Hum Pathol; 2013 Jun; 44(6):1017-23. PubMed ID: 23290009
[TBL] [Abstract][Full Text] [Related]
9. ARID1A gene mutation in ovarian and endometrial cancers (Review).
Takeda T; Banno K; Okawa R; Yanokura M; Iijima M; Irie-Kunitomi H; Nakamura K; Iida M; Adachi M; Umene K; Nogami Y; Masuda K; Kobayashi Y; Tominaga E; Aoki D
Oncol Rep; 2016 Feb; 35(2):607-13. PubMed ID: 26572704
[TBL] [Abstract][Full Text] [Related]
10. Annexin A4 and cancer.
Wei B; Guo C; Liu S; Sun MZ
Clin Chim Acta; 2015 Jul; 447():72-8. PubMed ID: 26048190
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors.
Perez-Juarez CE; Arechavaleta-Velasco F; Zeferino-Toquero M; Alvarez-Arellano L; Estrada-Moscoso I; Diaz-Cueto L
Med Oncol; 2019 Nov; 37(1):4. PubMed ID: 31713081
[TBL] [Abstract][Full Text] [Related]
12. Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.
Coppin C; Kollmannsberger C; Le L; Porzsolt F; Wilt TJ
BJU Int; 2011 Nov; 108(10):1556-63. PubMed ID: 21952069
[TBL] [Abstract][Full Text] [Related]
13. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Gui T; Shen K
Cancer Epidemiol; 2012 Oct; 36(5):490-6. PubMed ID: 22818908
[TBL] [Abstract][Full Text] [Related]
14. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.
Monk BJ; Coleman RL
Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2():S63-7. PubMed ID: 19955917
[TBL] [Abstract][Full Text] [Related]
15. An overview of early investigational therapies for chemoresistant ovarian cancer.
Marchetti C; Ledermann JA; Benedetti Panici P
Expert Opin Investig Drugs; 2015; 24(9):1163-83. PubMed ID: 26206420
[TBL] [Abstract][Full Text] [Related]
16. Annexin A4 fucosylation enhances its interaction with the NF-kB p50 and promotes tumor progression of ovarian clear cell carcinoma.
Wang H; Deng L; Cai M; Zhuang H; Zhu L; Hao Y; Gao J; Liu J; Li X; Lin B
Oncotarget; 2017 Dec; 8(64):108093-108107. PubMed ID: 29296226
[TBL] [Abstract][Full Text] [Related]
17. ARID1A mutant ovarian clear cell carcinoma: A clear target for synthetic lethal strategies.
Caumanns JJ; Wisman GBA; Berns K; van der Zee AGJ; de Jong S
Biochim Biophys Acta Rev Cancer; 2018 Dec; 1870(2):176-184. PubMed ID: 30025943
[TBL] [Abstract][Full Text] [Related]
18. Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives.
McClung EC; Wenham RM
Int J Womens Health; 2016; 8():59-75. PubMed ID: 27051317
[TBL] [Abstract][Full Text] [Related]
19. Targeted sequencing of a specific gene panel detects a high frequency of ARID1A and PIK3CA mutations in ovarian clear cell carcinoma.
Su YF; Tsai EM; Chen CC; Wu CC; Er TK
Clin Chim Acta; 2019 Jul; 494():1-7. PubMed ID: 30851247
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]